Tumor necrosis factor-α blockade in the treatment of rheumatoid arthritis

Rheumatic Disease Clinics of North America

Volumn 27, Issue 2, 2001, Pages 427-443

  Keystone, Edward C ^b  

^a MOUNT SINAI HOSPITAL   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINUCLEAR ANTIBODY; ETANERCEPT; IMMUNOGLOBULIN G; INFLIXIMAB; LENERCEPT; METHOTREXATE; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; TUMOR NECROSIS FACTOR ANTIBODY;

ALGORITHM; CHILL; CLINICAL TRIAL; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; DYSPNEA; FEVER; GENETIC ENGINEERING; HUMAN; PRIORITY JOURNAL; PRURITUS; REVIEW; RHEUMATOID ARTHRITIS; SKIN MANIFESTATION; UPPER RESPIRATORY TRACT INFECTION; URTICARIA;

EID: 0035001554     PISSN: 0889857X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-857X(05)70211-8     Document Type: Article

References (57)

1. B.G.W. Arnason TNF neutralization in MS: Results of a randomized, placebo controlled, multicenter study. Lenercept Multiple Sclerosis Study Group Neurology 53 1999 457
2. A.M. Badger D.E. Griswold R. Kapadia Disease-modifying activity of SB 242235, a selective inhibitor of p38 mitogen-activated protein kinase, in rat adjuvant-induced arthritis Arthritis Rheum 43 2000 175
3. J.M. Bathon R.W. Martin R.M. Fleischmann A Comparison of etanercept and methotrexate in patients with early rheumatoid arthritis N Engl J Med 18 2001 344
4. A. Bendele E.S. Chlipala W.R. Rich Combination benefit of treatment with recombinant human interleukin-1 receptor antagonist (IL-1ra) and PEGylated recombinant human soluble tumor necrosis factor type 1 (PEG sTNF-R1) in animal models of rheumatoid arthritis [abstract] Arthritis Rheum 42 suppl 2000 S171
5. B. Beutler The role of tumor necrosis factor in health and disease J Rheumatol 26 1999 16
6. B. Beutler A. Cerami The biology of cachectin/TNFα? a primary mediator of the host response Annu Rev Immunol 7 1989 625
7. M. Boers A.C. Verhoeven H.M. Markusse Randomized comparison of combined step down prednisone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis Lancet 350 1997 309
8. F.M. Brennan D. Chantry A. Jackson Inhibitory effect of TNFα antibodies on synovial cell interleukin-1 production in rheumatoid arthritis Lancet ii 1989 244
9. F.M. Brennan D. Gibbons A.P. Cope TNFα and TNF receptor expression and regulation in rheumatoid arthritis Balint G. Gomor B. Hodinka L. Rheumatology, State of the Art 1997 Elsevier Science Amsterdam 115
10. Butler D.M. Malfait A.-M. R.N. Maini Anti-IL-12 and anti-TNF antibodies synergistically suppress the progression of murine collagen-induced arthritis Eur J Immunol 29 1999 2205
11. Caldwell JR, Davis MW, Jalaca-Maxwell K, et al: A phase I study of PEGylated soluble tumor necrosis factor receptor type I (PEGs TNF-RI [p55]) in subjects with rheumatoid arthritis. Arthritis Rheum, in press
12. M. Calgiineri S. Pay Z. Caliskanen Combination therapy versus monotherapy for the treatment of patients with rheumatoid arthritis Clin Exp Rheumatol 17 1999 699
13. C.Q. Chu M. Field M. Feldmann Localization of tumor necrosis factor α in synovial tissues and at the cartilage-pannus junction in patients with rheumatoid arthritis Arthritis Rheum 34 1991 1125
14. M.R. Dalesandro C.S. Kinney B. Froderick Potential clinical relevance of the mechanism of inhibition of immune function by the mouse (human chimeric anti-TNF alpha antibody cA? Arthritis Rheum 38 1995 401
15. Edwards C.K. III PEGylated recombinant human soluble tumor necrosis factor receptor type I (p-HU-sTNF-RI): A novel high affinity TNF receptor designed for chronic inflammatory diseases Ann Rheum Dis 58 suppl 1999 173
16. M.J. Elliot R.N. Maini M. Feldmann Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor (cA?) versus placebo in rheumatoid arthritis Lancet 344 1994 1105
17. M.J. Elliot R.N. Maini M. Feldmann Repeated therapy with monoclonal antibody to tumor necrosis factor (cA?) in patients with rheumatoid arthritis Lancet 344 1994 1125
18. M.J. Elliot R.N. Maini M. Feldmann Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor α Arthritis Rheum 36 1993 1681
19. M. Feldmann R.N. Maini The role of cytokines in the pathogenesis of rheumatoid arthritis Rheumatology 38 Suppl 2 1999 3
20. D.E. Furst E. Keystone R.N. Maini Recapitulation of the round-table discussion assessing the role of anti-tumor necrosis factor therapy in the treatment of rheumatoid arthritis Rheumatology 38 Suppl 2 1999 50
21. Gershon S, Wise RP, Niu M, et al: Postlicensure reports of infection during use of etanercept and infliximab. Presented at the American College of Rheumatology Meeting, October 2000
22. B. Hazleman M. Smith K. Moss Efficacy of a novel PEGylated humanised anti-TNF fragment (CDP870) in patients with rheumatoid arthritis Rheumatology 39 suppl 2000 87
23. J. Keffer L. Probert H. Cazlaris Transgenic mice expressing human tumor necrosis factor: A predictive genetic model of arthritis EMBO 10 1991 4025
24. J. Kneer E. Luedin W. Lesslauer An assessment of the effect of antidrug antibody formation on the pharmacokinetics and pharmacodynamics of sTNF p55-IgG (lenercept) in patients with rheumatoid arthritis Arthritis Rheum 41 suppl 1998 S58
25. Lipsky P. St Clair W. Furst D. 54-week clinical and radiological results from the Attract trial. A phase III study of infliximab (Remicade) in patients with active RA despite methotrexate [abstract] Arthritis Rheum 42 suppl 1999 S401
26. Lorenz H.-M. C. Antoni T. Valeruis In vivo blockade of TNF-alpha by intravenous infusion of a chimeric monoclonal TNF-alpha antibody in patients with rheumatoid arthritis: Short term cellular and molecular effects J Immunol 156 1996 1646
27. Lorenz H.-M. M. Griinke T. Hieronymus In vivo blockade of tumor necrosis factor α in patients with rheumatoid arthritis: Long term effects after repeated infusion of chimeric monoclonal antibody cA? J Rheumatol 27 2000 304
28. R.N. Maini P.C. Taylor E. Paleolog Anti-tumor necrosis factor specific antibody (infliximab) treatment provides insights into the pathophysiology of rheumatoid arthritis Ann Rheum Dis 58 Suppl 1 1999 156
29. Maini R.N. St Clair E. Breedveld F. Randomized phase III trial of infliximab (chimeric anti-TNFα monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate Lancet 354 1999 1932
30. R.N. Maini F.C. Breedveld J.R. Kalden Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor α monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis Arthritis Rheum 41 1998 1552
31. J. McKay R. Rau M. Weisman A double-blind randomized, six arm, parallel-group, dose finding, double dummy, multi-center comparison of sTNF p55-IgG (R045-2081—lenercept) subcutaneous to reference treatment with oral methotrexate (MTX) and their combination in patients with rheumatoid arthritis Arthritis Rheum 41 suppl 1998 S132
32. N. Mohan E.T. Edwards T.R. Cupps Demyelination diagnosed during etanercept (TNF receptor fusion protein) therapy Arthritis Rheum 43 suppl 2000 S228
33. L.M. Moreland S.B. Cohen S.W. Baumgartner Long term use of etanercept in patients with DMARD refractory rheumatoid arthritis [abstract] Arthritis Rheum 42 suppl 1999 S401
34. L.W. Moreland M.H. Schiff S.W. Baumgartner Etanercept therapy in rheumatoid arthritis: A randomized controlled trial Ann Intern Med 130 1999 478
35. L.W. Moreland D.P. McCabe J.R. Caldwell Phase I/II trial of recombinant methionyl human tumor necrosis factor binding protein PEGylated dimer in patients with active refractory rheumatoid arthritis J Rheumatol 27 2000 601
36. L.W. Moreland S.W. Baumgartner M.H. Schiff Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)–Fc fusion protein N Engl J Med 337 1997 141
37. T. Mottonen P. Hannonen M. Leirisalo-Repo Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: A randomized trial Lancet 333 1999 1568
38. J.R. O'Dell C.E. Haire N. Erikson Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications N Engl J Med 334 1996 1287
39. S. Ohshima Y. Saeki T. Mima Long-term follow up of the changes in circulating cytokines soluble cytokine receptors and white blood cell subset counts in patients with rheumatoid arthritis (RA) after monoclonal anti-TNFα antibody therapy J Clin Immunol 19 1999 305
40. E.M. Paleolog M. Hunt M.J. Elliot Deactivation of vascular endothelium by monoclonal anti-tumor necrosis factor alpha antibody in rheumatoid arthritis Arthritis Rheum 39 1996 1082
41. E.M. Paleolog S. Young A.C. Stark Modulation of angiogenic vascular endothelial growth factor (alpha) and interleukin-1 in rheumatoid arthritis Arthritis Rheum 41 1998 1258
42. Perkins D.J. St Clair E.W. Misukonis M.A. Reduction of NOS? overexpression in rheumatoid arthritis patients treated with anti-tumor necrosis factor alpha monoclonal antibody (cA?) Arthritis Rheum 41 1998 2205
43. R. Rau O. Sander den Broeder A. Long term efficacy and tolerability of multiple IV doses of the fully human anti-TNF antibody D2E7 in patients with rheumatoid arthritis [abstract] Arthritis Rheum 41 suppl 1998 55
44. R. Rau G. Herborin O. Sander Long term treatment with the fully human anti-TNF antibody D2E7 slows radiographic disease progression in rheumatoid arthritis Arthritis Rheum 42 suppl 1999 S400
45. M. Schattenkirchner K. Kruger O. Sander Efficacy and tolerability of weekly subcutaneous injections of the fully human anti-TNF antibody D2E7 in patients with rheumatoid arthritis [abstract] Arthritis Rheum 41 suppl 1998 S7
46. P.P. Tak G. Taylor F.C. Breedveld Decrease in cellularity and expression of adhesion molecules by anti-tumor necrosis factor alpha monoclonal antibody treatment in patients with rheumatoid arthritis 39 1996 1077
47. P.C. Taylor A.M. Peters E. Paleolog Reduction of chemokine levels and leukocyte traffic to joints by tumor necrosis factor α blockade in patients with rheumatoid arthritis Arthritis Rheum 43 2000 38
48. Van de Putte L.A.B. R. Rau F.C. Breedveld Efficacy of the fully human anti-TNF antibody D2E7 in rheumatoid arthritis [abstract] Arthritis Rheum 42 suppl 1999 S400
49. Van de Putte L.A.B. van Riel P. den Broeder A. A single dose placebo-controlled phase I study of the fully human anti-TNF antibody D2E7 in patients with rheumatoid arthritis [abstract] 41 suppl 1998 S7
50. Van Ooasten B.W. F. Barkholf L. Truyen Increased MRI activity and immune activation in two multiple sclerosis patients treated with monoclonal anti-tumor necrosis factor antibody cA2 Neurology 47 1996 1531
51. K.J. VanZee T. Kohno E. Fischer Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor alpha in vitro and in vivo Proc Natl Acad Sci USA 89 1992 4845
52. M.E. Weinblatt J.M. Kremer M. Lange Long term safety and efficacy of combination therapy with methotrexate (MTX) and etancercept (Enbrel) [abstract] Arthritis Rheum 42 suppl 1999 S401
53. M.E. Weinblatt J.M. Kremer A. Bankhurst A trial of etanercept. A recombinant tumor necrosis factor receptor:Fc fusion protein in patients with rheumatoid arthritis receiving methotrexate N Engl J Med 340 1999 253
54. M. Weisman A. Wiik M. Zang TNF neutralization does not cause auto-antibodies changes: Experience with 247 patients enrolled into a 12 week DB subcutaneous (sc) lenercept trial Arthritis Rheum 41 1998 585
55. R.O. Williams M. Feldmann R.N. Maini Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis Proc Natl Acad Sci USA 89 1992 9784
56. R.O. Williams L. Mason M. Feldmann Synergy between anti CD4 and anti-tumor necrosis factor in the amelioration of established collagen-induced arthritis Proc Natl Acad Sci USA 91 1994 2762
57. R.O. Williams C. Mauri L.J. Mason Therapeutic actions of cyclosporine and anti-tumor necrosis factor α in collagen-induced arthritis and the effect of combination therapy Arthritis Rheum 41 1998 1806